A drug review is imminent to assess whether provinces should fund ODOMZO® (sonidegib), a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has come back following surgery or radiation or that cannot be treated with surgery or radiation.
Melanoma Network of Canada is providing a submission to aid in the process for determining provincial listing and coverage of this drug therapy. Your Input will help us prepare a group submission to the pan-Canadian Oncology Drug Review (pCODR) on the experiences and opinions of BCC patients and their caregivers. As many of you already know, effective treatment therapies for locally advanced or metastatic basal cell carcinoma are very limited and patients are in great need of options for treatment and quality of life. While the majority of BCC patients will be treated effectively with topical solutions, surgery or radiation, for the small number of patients where these treatments do not work, this new therapy holds significant promise for effective treatment and improved quality of life.
This survey is open to all patients and caregivers, no matter what stage. PLEASE NOTE THIS SURVEY CLOSES JULY 26TH, 2020